TNFRSF8 and mature T-cell and NK-cell non-Hodgkin lymphoma: Brentuximab vedotin (BV), a chimeric anti‐CD30 antibody conjugated with the anti‐tubulin agent monomethyl auristatin E, has shown effectiveness in Hodgkin's lymphoma (HL) and PTCL.